ClinicalTrials.gg
CompletedNCT04839341Updated Jun 27, 2025

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

A Phase 1 interventional study of Uproleselan in Relapsed/Refractory AML, sponsored by Apollomics Inc.. Completed at 2 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Apollomics Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Enrollment
370th of 433
12 · median 50
Started
2021
with 43 others
Phase 1
121 of 473
69 open now
Registered
131st of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 370th largest by enrollment of the 433 interventional ones that give a count, is one of 44 that started in 2021, is one of 121 in phase 1, and was the 131st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

Read the detailed description

This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period.

Screening phase:

This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening.

Baseline period:

The baseline period is 1 day before study drug administration.

Induction treatment:

During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy.

Consolidation baseline:

The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase.

Consolidation treatment:

Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest.

Follow-up period:

Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).

03

Conditions studied

  • Relapsed/Refractory AML

Keywords

  • AML
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years and ≤60 years in age
  2. AML (including secondary AML) diagnosed as per WHO standards (2008).
  3. For AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

    1. For relapse AML, it must be the first or second relapse, and remain untreated.
    2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
  4. performance status score is 0 to 2.
  5. Stable hemodynamics and good organ function.

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary AML.
  2. Active signs or symptoms of CNS involvement by .
  3. Stem cell transplantation ≤4 months prior to dosing.
  4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
  5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  6. Inadequate organ function.
  7. Abnormal liver function.
  8. Known active infection with hepatitis A, B, or C, or .
  9. Moderate kidney dysfunction ( \<45 mL/min).
  10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  11. cardiovascular disease.
  12. Major surgery within 4 weeks of dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    A Phase I, open-labeled multicenter study

    Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)

    Drug: Uproleselan

Interventions

  • A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin

    Also known as: GMI-1271

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Tmax)

    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

    Time frame: 14 days

  2. Peak plasma concentration (Cmax)

    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

    Time frame: 14 days

  3. Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12)

    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

    Time frame: 14 days

  4. The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point

    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

    Time frame: 14 days

  5. The Incidence of Adverse Events

    Number of participants with an AE.

    Time frame: Up to 10 months

  6. The tolerance of participants with relapsed/refractory AML.

    Number of participants could tolerate the Uproleselan combined with chemotherapy.

    Time frame: Up to 10 months

Secondary outcomes

  1. OS

    Defined as the period from when the subject receives the first dose of the study drug to death from any cause;

    Time frame: Up to 3 years

  2. Remission rate (rate of CR, CR/CRi and CR/CRh)

    Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh;

    Time frame: Up to 60 days

  3. CTCAE grade 3 and 4 oral mucositis

    The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration.

    Time frame: Up to 254 days

07

Study locations

2 sites
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tianjin, Tianjin Municipality 300020, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jun 2024, 40 months.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 40 months is close to that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Apr 9, 2021
StartActual
Feb 24, 2021
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04839341
Lead sponsor
Apollomics Inc.
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Feb 24, 2021
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Last update
Jun 27, 2025

Study contacts

Jianxiang Wang, PhD
principal investigator · Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Uproleselan

Start the discussion